Recombinant growth hormone treatment for AIDS/HIV-associated wasting and lipodystrophy
Record ID 32013000154
English
Authors' recommendations:
Recombinant human growth hormone (rhGH) is used in the treatment of AIDS-associated wasting and lipodystrophy; tesamorelin, an analog of growth hormone–releasing factor (GHRF), is used for treatment of AIDS-associated lipodystrophy. The goal of these treatments is to increase lean body mass in patients with human immunodeficiency virus (HIV)-associated wasting and to reduce AIDSrelated abnormal morphologic and metabolic changes in HIV patients with lipodystrophy.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=2169
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2012 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.